Imperial College London
Alternate

Emeritus ProfessorMyraMcClure

Faculty of Medicine, Department of Infectious Disease

Emeritus Professor of Retrovirology
 
 
 
//

Contact

 

+44 (0)20 7594 3902m.mcclure

 
 
//

Location

 

456Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Clarke:2021:10.1016/j.kint.2021.03.009,
author = {Clarke, CL and Prendecki, M and Dhutia, A and Gan, J and Edwards, C and Prout, V and Lightstone, L and Parker, E and Marchesin, F and Griffith, M and Charif, R and Pickard, G and Cox, A and McClure, M and Tedder, R and Randell, P and Greathead, L and Guckian, M and McAdoo, SP and Kelleher, P and Willicombe, M},
doi = {10.1016/j.kint.2021.03.009},
journal = {Kidney International},
pages = {1470--1477},
title = {Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection},
url = {http://dx.doi.org/10.1016/j.kint.2021.03.009},
volume = {99},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were regularly screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies, and those who became seronegative at six months were screened for SARS-CoV-2 specific T-cell responses. One hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at time zero, of whom 127 also had detectable anti-RBD. Significantly, at six months, 71/111 (64.0%) and 99/116 (85.3%) remained anti-NP and anti-RBD seropositive, respectively. For patients who retained antibody, both anti-NP and anti-RBD levels were reduced significantly after six months. Eleven patients who were anti-NP seropositive at time zero, had no detectable antibody at six months; of whom eight were found to have SARS-CoV-2 antigen specific T cell responses. Independent of antibody status at six months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following six months. Thus, patients receiving ICHD mount durable immune responses six months post SARS-CoV-2 infection, with fewer than 3% of patients showing no evidence of humoral or cellular immunity.
AU  - Clarke,CL
AU  - Prendecki,M
AU  - Dhutia,A
AU  - Gan,J
AU  - Edwards,C
AU  - Prout,V
AU  - Lightstone,L
AU  - Parker,E
AU  - Marchesin,F
AU  - Griffith,M
AU  - Charif,R
AU  - Pickard,G
AU  - Cox,A
AU  - McClure,M
AU  - Tedder,R
AU  - Randell,P
AU  - Greathead,L
AU  - Guckian,M
AU  - McAdoo,SP
AU  - Kelleher,P
AU  - Willicombe,M
DO  - 10.1016/j.kint.2021.03.009
EP  - 1477
PY  - 2021///
SN  - 0085-2538
SP  - 1470
TI  - Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
T2  - Kidney International
UR  - http://dx.doi.org/10.1016/j.kint.2021.03.009
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33774082
UR  - https://www.sciencedirect.com/science/article/pii/S0085253821002957?via%3Dihub
UR  - http://hdl.handle.net/10044/1/87459
VL  - 99
ER  -
Download